DarlinG
Active member
Experimental drug slows progression of early Alzheimer's disease by 60%, study finds Eli Lilly's experimental drug donanemab slowed the progression of Alzheimer's by 60% for patients in the earliest stages of the brain-wasting disease, according to trial data presented at a medical meeting on Monday.